Transplant International

Kidney

1. Front Matter

   Pages 1-1

   PDF

2. Chronic rejection

   1. Rat cytomegalovirus infection and chronic kidney allograft rejection

      • Petri K. Koskinen, Serdar Yilmaz, Erkki Kallio, Cathrien A. Bruggeman, Pekka J. Häyry, Karl Lemström

      Pages 3-4

   2. Does delayed kidney graft function increase the risk of chronic rejection?

      • Helena Isoniemi, Satu Lehtonen, Kaija Salmela, Juhani Ahonen

      Pages 5-7

3. Match, Sensitation

   1. Evaluation of the permissible mismatch concept

      • T. Wujciak, G. Opelz

      Pages 8-10

   2. The significant effect of HLA-DRB1 matching on acute rejection in kidney transplants

      • Michio Nojima, Hideari Ihara, Masahiro Kyo, Mitsuo Hashimoto, Kiichiro Ito, Seiji Kunikata et al.

      Pages 11-15

   3. Five-year results of renal transplantation in highly sensitized recipients

      • Gerhard Opelz

      Pages 16-19

   4. Anticipation of highly sensitised renal patients’ immunoadsorption requirements by prescreening using protein A minicolumns

      • D. J. Bevan, B. S. Carey, R. W. Vaughan, A. N. Hillis, M. Fallon, R. M. Higgins et al.

      Pages 20-24

   5. Weak expression of blood type B antigen in kidney tissue and successful B-incompatible kidney transplantation without special treatments

      • I. Koyama, Y. Taguchi, S. Sugahara, N. Akimoto, R. Omoto

      Pages 25-27

4. HCV infection

   1. Outcome of renal graft recipients with hepatitis C virus infection

      • A. Rodrigues, T. Morgado, A. Castro Henriques, A. Morais Sarmento, M. Pereira, S. Guimarãcs

      Pages 28-31

5. Immunosuppressor

   1. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients

      • J. M. Kovarik, E. Rawlings, P. Sweny, O. Fernando, P. L. Amlot, R. Moore et al.

      Pages 32-33

   2. Acute rejection relapses posttransplant: definition of risk group and evaluation of potent therapeutic regimens

      • Ursula Jacobs, Detlef Niese, Wulf-Dietrich Miersch, Hans-Ulrich Klehr

      Pages 34-37

   3. Steroid-resistant rejection in kidney-transplanted patients: is ATG treatment for three or ten days preferable?

      • Michael Olausson, Lars Mjörnstedt, Hans Brynger, Ingemar Blohmé

      Pages 38-40

   4. Randomized trial of misoprostol in patients with chronic renal transplant rejection

      • L. B. Hilbrands, J. Rischen-Vos, R. Hené, W. Weimar, K. Assmann, A. J. Hoitsma

      Pages 41-44

6. Miscellaneous

   1. Increased tenascin expression is an early feature of the development of transplant renal arteriopathy in humans

      • S. Tanabe, Y.-S. Han, T. Nakatani, T. Kishimoto, M. Ueda, S. Suzuki et al.

      Pages 45-48

   2. Is kidney transplantation in sensitized recipients justified?

      • A. Bersztel, J. Wadström, G. Tufveson, G. Gannedahl, M. Bengtsson, C. Bergström et al.

      Pages 49-53

   3. Low-density lipoprotein oxidation is increased in kidney transplant recipients

      • Marinus A. van den Dorpel, Hosam Ghanem, Jacqueline Rischen-Vos, Arie J. Man in ’t Veld, Hans Jansen, Willem Weimar

      Pages 54-57

7. Monitoring

   1. The anaphylatoxin C5a, a new parameter in the diagnosis of renal allograft rejection

      • Thomas F. Müller, Christine M. Neumann, Christoph Greb, Michael Kraus, Harald Lange

      Pages 58-62

   2. A critical analysis of soluble interleukin-2 receptor levels in kidney allograft recipients

      • J. Kaden, B. Schütze, G. May

      Pages 63-67

   3. Diagnostic value of urinary enzyme determination in renal transplantation

      • E. Sárváry, P. Borka, B. Sulyok, A. Péter, Z. Vass, J. Járay et al.

      Pages 68-72